Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sean Maduck Sells 20,000 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $79.08, for a total value of $1,581,600.00. Following the transaction, the insider now directly owns 17,705 shares of the company's stock, valued at approximately $1,400,111.40. This trade represents a 53.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sean Maduck also recently made the following trade(s):

• On Friday, May 2nd, Sean Maduck sold 26,554 shares of Corcept Therapeutics stock. The stock was sold at an average price of $72.23, for a total value of $1,917,995.42.
• On Monday, March 31st, Sean Maduck sold 100,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $100.54, for a total value of $10,054,000.00.

Corcept Therapeutics Trading Up 0.9%

Shares of Corcept Therapeutics stock traded up $0.59 during midday trading on Friday, reaching $69.60. The company had a trading volume of 972,774 shares, compared to its average volume of 1,150,167. The firm has a market cap of $7.38 billion, a PE ratio of 55.24 and a beta of 0.19. The stock has a fifty day moving average price of $72.03 and a 200 day moving average price of $63.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics Incorporated has a fifty-two week low of $28.04 and a fifty-two week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, hitting analysts' consensus estimates of $0.17. The business had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.25 earnings per share. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Focus Partners Wealth boosted its position in Corcept Therapeutics by 0.5% in the first quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company's stock worth $3,797,000 after purchasing an additional 170 shares during the last quarter. Brooklyn Investment Group lifted its position in shares of Corcept Therapeutics by 99.5% during the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after buying an additional 186 shares during the last quarter. Black Diamond Financial LLC lifted its holdings in Corcept Therapeutics by 4.0% during the 4th quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company's stock worth $262,000 after purchasing an additional 200 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Corcept Therapeutics by 3.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 7,954 shares of the biotechnology company's stock worth $909,000 after purchasing an additional 230 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Corcept Therapeutics by 9.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company's stock worth $150,000 after purchasing an additional 257 shares in the last quarter. Institutional investors own 93.61% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CORT. Truist Financial set a $135.00 price target on Corcept Therapeutics in a report on Tuesday, May 6th. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Piper Sandler raised their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. HC Wainwright decreased their target price on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Wall Street Zen lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Corcept Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.